AR053263A1 - Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologico - Google Patents

Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologico

Info

Publication number
AR053263A1
AR053263A1 ARP060101786A ARP060101786A AR053263A1 AR 053263 A1 AR053263 A1 AR 053263A1 AR P060101786 A ARP060101786 A AR P060101786A AR P060101786 A ARP060101786 A AR P060101786A AR 053263 A1 AR053263 A1 AR 053263A1
Authority
AR
Argentina
Prior art keywords
receptor agonists
vpac2
hypofisary
cyclass
pacap
Prior art date
Application number
ARP060101786A
Other languages
English (en)
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AR053263A1 publication Critical patent/AR053263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente proporciona péptidos con nuevas modificaciones que proveen sitios de derivacion adecuados para mejorar las propiedades farmacocinéticas de los péptidos. Estos péptidos modificados funcionan in vivo como agonistas del receptor VPAC2. Los péptidos de la presente proporcionan un nuevo tratamiento para pacientes con disminucion de la secrecion de insulina endogena, por ejemplo, pacientes con diabetes tipo 2.
ARP060101786A 2005-05-06 2006-05-03 Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologico AR053263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67886005P 2005-05-06 2005-05-06

Publications (1)

Publication Number Publication Date
AR053263A1 true AR053263A1 (es) 2007-04-25

Family

ID=37397050

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101786A AR053263A1 (es) 2005-05-06 2006-05-03 Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologico

Country Status (10)

Country Link
US (1) US20090280106A1 (es)
EP (1) EP1896048A4 (es)
JP (1) JP2008539723A (es)
AR (1) AR053263A1 (es)
CA (1) CA2607273A1 (es)
DO (1) DOP2006000106A (es)
PE (1) PE20061419A1 (es)
TW (1) TW200716156A (es)
UY (1) UY29519A1 (es)
WO (1) WO2006121588A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082276A1 (en) * 2006-02-28 2009-03-26 Lianshan Zhang Selective vpac2 receptor peptide agonists
GB0724953D0 (en) * 2007-12-20 2008-01-30 Lytix Biopharma As Methods of peptide modification
WO2011054001A2 (en) * 2009-11-02 2011-05-05 The Administrators Of The Tulane Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
EP2709636A2 (en) * 2011-05-19 2014-03-26 Ariel-University Research and Development Company Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
CN105601571B (zh) * 2015-12-22 2019-03-05 北京医药集团有限责任公司 苯并咪唑类衍生物、其制备方法和应用
WO2019032915A1 (en) * 2017-08-09 2019-02-14 Arizona Board Of Regents Of Behalf Of The University Of Arizona GLYCOPEPTIDE ANALOGUES OF PEPTIDES FROM THE SECRETIN FAMILY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2269354C2 (ru) * 1999-09-28 2006-02-10 Байер Корпорейшн Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
AU2002220720B2 (en) * 2000-11-28 2006-09-14 Mondobiotech Ag Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
PE20040677A1 (es) * 2002-07-12 2004-10-29 Bayer Pharmaceuticals Corp Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap)
BRPI0507177A (pt) * 2004-01-27 2007-06-26 Bayer Pharmaceuticals Corp agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso
WO2005113593A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080026996A1 (en) * 2004-05-21 2008-01-31 Eli Lilly And Company Selective Vpac2 Receptor Reptide Agonists
US20080261863A1 (en) * 2004-06-12 2008-10-23 Bayer Pharmaceuticals Corp Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use
CA2576217A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists

Also Published As

Publication number Publication date
WO2006121588A2 (en) 2006-11-16
JP2008539723A (ja) 2008-11-20
PE20061419A1 (es) 2007-01-28
UY29519A1 (es) 2006-11-30
EP1896048A2 (en) 2008-03-12
TW200716156A (en) 2007-05-01
CA2607273A1 (en) 2006-11-16
DOP2006000106A (es) 2007-04-15
WO2006121588A3 (en) 2007-02-15
EP1896048A4 (en) 2010-11-03
US20090280106A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
GT200300142A (es) Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
WO2006121860A3 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
AR053263A1 (es) Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologico
ECSP024346A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
AR084558A1 (es) Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
CR10694A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
AR099977A1 (es) Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4
CL2012002031A1 (es) Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente.
CL2012002635A1 (es) Péptido que presenta actividad para el receptor del péptido insulinotrópico dependiente de glucosa (gip-r) y para el receptor del péptido-1 similar al glucagón (glp-1-r) y son selectivos sobre el receptor del glucagón (gluc-r); formulación farmacéutica que lo comprende; y su uso para el tratamiento de diabetes mellitus y para la pérdida de peso.
BRPI0924307A8 (pt) Análogos de oxintomodulina
AR105284A1 (es) Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
CO6400136A2 (es) Agosnistas del receptor gpr120 y usos de los mismos
UY31596A1 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
CL2008002111A1 (es) Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
CL2008001612A1 (es) 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
NI201100075A (es) Agonistas del receptor gpr120 de arilo y usos de los mismos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal